ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against c…
FAIL · Does not pass the screen
9.28 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 5 days ago
Screened 2026-10-01 · the tape above runs as of 19:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 9.28 against the desk's fair-value range, base estimate 12.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price9.28 USD
Fair value12.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-01Read Accumulation8.19+13.3% to today ✓
2026-08-01Read Markdown7.45+24.6% to today
2026-07-02Read Accumulation7.10+30.7% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
ImmunityBio, Inc. holds its Accumulation at $9.28. The statistical read favours the buyers, held for 2 days.
As held on the ledger · 2026-10-01
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 2 days
Price at the screen
$9.28
Valuation
N/A trailing · -73.26 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.14
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
103.22%
Below 33%
Interest-bearing debt is 103.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
30.78%
Below 33%
Cash held in interest-bearing accounts and securities is 30.8% of assets, under the one-third limit.
Pass
Receivables
26.08%
Below 49%
Money owed to the company is 26.1% of assets, under the 49% limit.
Pass
Revenue purity
2.37%
Below 5%
Only 2.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
ImmunityBio,'s business is in a permissible area, but its interest-bearing debt is about 103% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 29.3% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +29% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech dreams meet sky high valuations
Picture a lab racing to train the body to fight cancer on its own. ImmunityBio is building those next generation immunotherapies, and revenue is surging 168 percent. Yet the shares trade at 128 times forward earnings with zero profit margin and sit 13 percent above our fair value, so the opportunity rating stays at none.
The business is still pre profit and the moat remains unknown. Three analysts see a median target of twelve dollars, but that optimism sits against a company that has yet to prove it can turn rapid top line growth into cash. Ethical screens clear, yet the numbers do not support stepping in.
High revenue growth often masks the real risks here, from clinical trial setbacks to dilution that can erase gains fast. Cyclical or not, paying a premium for unproven science rarely ends well. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IBRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Accumulation$9.28+13.3%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 110%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $13.
2026-09-01Accumulation · changed$8.19+9.9%Entry 5
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 110%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $13.
2026-08-01Markdown · changed$7.45+4.9%Entry 4
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 110%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $13.
2026-07-18Accumulation$7.10+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 62% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 110%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (3 analysts) rates it strong buy, with a mean price target of $13.
2026-07-03Accumulation$7.10+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$7.10Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.